



03-19-04

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: I-Ping Chung, Jesse Steven Chambers, Carol )  
Ann Schnepfer, Roger L. Poe, Jaiwant D. ) Art Unit: Unknown  
• Jayakaran, Richard T. Waibel, Michael G. )  
Claxton, Marianne Zimola and Darin Robert )  
Foote, )  
Serial No.: 10/775,978 )  
Filed: February 10, 2004 )  
For: COMPACT LOW NO<sub>x</sub> GAS BURNER ) Examiner: Unknown  
APPARATUS AND METHODS )

**NOTIFICATION OF FILING CONTINUING,  
DIVISIONAL OR CONTINUED PROSECUTION APPLICATION**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, Virginia 22313-1450


Notification is hereby being made of the filing of a :

  X   Continuation  
      Continuation-in-Part  
      Divisional  
      Continued Prosecution Application

for this case


  X   concurrently herewith.  
      on \_\_\_\_\_ (date).

I hereby certify that this correspondence is being deposited  
in the United States Postal Service as first class mail in an  
envelope addressed to:  
Commissioner for Patents, P.O. Box 1450,  
Alexandria, VA 22313-1450.

  
Stephanie A. Miller

Date: March 9, 2004

Respectfully submitted,

  
C. Clark Dougherty, Jr.

Registration No. 24,208  
McAFEE & TAFT  
Tenth Floor, Two Leadership Square  
211 North Robinson  
Oklahoma City, Oklahoma 73102  
405-235-9621 (Telephone)  
405-235-0439 (Facsimile)  
E-Mail: clark.dougherty@mcafeetaft.com  
Attorney for Applicants



Express Mail No. ER 830 260 108 US  
Attorney Docket No. 001-041501US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/608,257 Confirmation No. :  
Applicant : Guy P. Vanney et al. Art Unit :  
Filed : 27 June 2003 Examiner : Unknown  
TITLE : CATHETER DESIGN THAT FACILITATES POSITIONING AT TISSUE  
TO BE DIAGNOSED OR TREATED  
Docket No. : 001-041501US  
Customer No. : 33486

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**CERTIFICATE OF MAILING BY EXPRESS MAIL**

Sir:

The undersigned hereby certifies that the attached:

1. Information Disclosure statement (5 pages);
2. Form PTO-1449 (1 page);
3. U.S. Patent Nos. 5,348,554; 5,487,757; 5,545,161; 5,545,200; 5,785,706;  
5,826,576; 5,906,605; 5,938,694; 5,993,462; 6,080,151; 6,120,500; 6,169,916;  
6,251,109; 6,264,654; 6,325,797; and 6,447,507;
4. Certificate of Mailing by express mail; and
5. Return postcard,

all relating to the above application were deposited as "Express Mail", using the mailing label number noted in the header above, with the United States Postal Service, addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 08 March 2004.

8 March 2004  
Date

Adam D. Malmut  
Mailer

Adam D. Malmut  
**HEIMBECHER & ASSOC., LLC**  
**Customer No. 33486**  
200 Union Blvd., Suite 316  
Lakewood, CO 80228-1831  
Tel: 303-279-8888  
Fax: 303-985-0651



Express Mail Label No. ER 830 260 108 US

Application No. 10/608,257

Attorney Docket No. 001-041501US

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Appl. No. : 10/608,257 Confirmation No. :  
Applicant : Guy P. Vanney et al. Art Unit :  
Filed : 27 June 2003 Examiner : Unknown  
TITLE : CATHETER DESIGN THAT FACILITATES POSITIONING AT TISSUE TO  
BE DIAGNOSED OR TREATED  
Docket No. : 001-041501US  
Customer No. : 33486

---

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT  
PURSUANT TO 37 C.F.R. §§ 1.56, 1.97, AND 1.98**

Sir:

The Examiner is respectfully requested to consider the patents, patent applications, publications, or other information cataloged on the enclosed Form PTO-1449 during examination of the above-identified patent application. The order of presentation of the references should not be construed as an indication of importance. These references are submitted for the Examiner's consideration and are submitted pursuant to an Applicant's duty of disclosure under 37 C.F.R. § 1.56.

Copies of all of the cited documents

☒ are enclosed unless otherwise indicated on the enclosed Form PTO-1449.

☐ have been previously furnished to the Office in prior application No. \_\_\_\_\_, filed \_\_\_\_\_, which the present application relies upon for an earlier effective filing date under 35 U.S.C. § 120. Therefore, no copies of the cited documents are included herewith pursuant to 37 C.F.R. § 1.98(d); MPEP § 609(III)(A)(2).

☐ are enclosed unless they are U.S. patents or U.S. patent application publications, which are not enclosed since this application was filed after 30 June 2003. See "Information Disclosure Statements May Be Filed Without Copies of U.S. Patents and Published Applications in Patent Applications filed after June 30, 2003," 1276 Off. Gaz. Pat. Off. 55 (5 Aug. 2003).

**I  
BASIS**

This information disclosure statement is filed pursuant to

☒ 37 C.F.R. § 1.97(b).

This information disclosure statement is filed either (1) within three months of the filing date of a national application other than a continued prosecution application under 37 C.F.R. § 1.53(d); (2) within three months of the date of entry of the national stage as set forth in 37 C.F.R. § 1.491 in an international application; (3) before the mailing date of a first Office action on the merits; or (4) before the mailing of a first Office action after the filing of a request for continued examination under 37 C.F.R. § 1.114, whichever event occurs last.

Accordingly, this information disclosure statement requires no fee and no certification.

☐ 37 C.F.R. § 1.97(c).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(b), but before the mailing date of any of (1) a final action under 37 C.F.R. § 1.113; (2) a notice of allowance under 37 C.F.R. § 1.311; or (3) an action that otherwise closes prosecution in the application.

Accordingly, this information disclosure statement requires either the fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.97(c), or a statement under 37 C.F.R. § 1.97(e).

☐ 37 C.F.R. § 1.97(d).

This information disclosure statement is filed after the period specified in 37 C.F.R. § 1.97(c) since a

☐ final action under 37 C.F.R. § 1.113

☐ notice of allowance under 37 C.F.R. § 1.311

was mailed to the Applicant(s) on \_\_\_\_\_. The issue fee has not been paid herein.

Accordingly, this information disclosure statement requires the fee set forth in 37 C.F.R. § 1.17(p) to consider an information disclosure statement under 37 C.F.R. § 1.97(d), and a statement under 37 C.F.R. § 1.97(e).

If this statement crosses in the mail with an Office action, or is otherwise not in the indicated category of 37 C.F.R. § 1.97, it is respectfully requested that this statement be treated in the next appropriate category and made of record. To the extent required, please treat this paper as a conditional petition for acceptance of the information disclosure statement.

## **II FEES**

Any required fee is being paid as indicated below by an enclosed check or our deposit account.

- ☒ [ x] No fee is due.
- ☐ [ ] The \$\_\_\_\_\_ fee specified in 37 C.F.R. § 1.17(p) for submission of an information disclosure statement under 37 C.F.R. § 1.197(c) or (d) is due.
- ☐ [ ] A check is enclosed for the required fee.
- ☐ [ ] Please charge the required fee to our deposit account no. 502885. A duplicate copy of this information disclosure statement is enclosed.
- ☒ [ x] The Commissioner is hereby authorized to charge any additional required fees or credit any overpayments associated with this information disclosure statement to our deposit account no. 502885. A duplicate copy of this information disclosure statement is enclosed.

## **III CERTIFICATION**

Pursuant to 37 C.F.R. § 1.97(e), I state as follows:

- ☒ [ x] No statement is necessary.
- ☐ [ ] Each item of information contained in this information disclosure statement was first cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this information disclosure statement. 37 C.F.R. § 1.97(e)(1).
- ☐ [ ] No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this information disclosure statement was known to any individual designated in 37 C.F.R. § 1.56(c) more than three months prior to the filing of this information disclosure statement. 37 C.F.R. § 1.97(e)(2).

Pursuant to 37 C.F.R. § 1.704(d), I state as follows:

- ☐ [ ] Each item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart application, and this communication was not received by any individual designated in

37 C.F.R. § 1.56(c) more than thirty days prior to the filing of this information disclosure statement.

#### IV

#### FOREIGN LANGUAGE REFERENCES

Pursuant to 37 C.F.R. § 1.98(a)(3)(i), any information disclosure statement filed under 37 C.F.R. § 1.97 shall include a concise explanation of the relevance, as it is presently understood by the individual designated in § 1.56(c) most knowledgeable about the content of the information, of each patent, publication, or other information listed that is not in the English language. The concise explanation may be either separate from the specification or incorporated therein. In compliance with the rules, the Applicant(s) state as follows:

- ☒ [ x ] No concise explanation is required since all cited references are in English.
- ☐ [ ] A concise explanation of the relevance of one or more foreign language references is attached.
- ☐ [ ] According to the procedural policy adopted by the PTO with regard to disclosure requirements, the Applicant is satisfying the disclosure requirement pursuant to MPEP § 609(III)(A)(3) by submitting herewith the following:
  - ☐ [ ] English language versions of any non-English language documents.
  - ☐ [ ] English language versions of one or more search reports or other actions by one or more foreign patent offices in one or more counterpart foreign applications, which indicate the degree of relevance found by the foreign office(s).

The Applicant has not analyzed these documents and, therefore, declines to comment on their relevance at this time.

- ☐ [ ] One or more English language abstracts for the non-English language references are also enclosed.

#### V

#### REMARKS

It is respectfully requested that

- (1) the Examiner sign the enclosed Form PTO-1449 to evidence that the cited information has been fully considered by the Patent and Trademark Office during the examination of this application; and
- (2) the citations for the cited information be printed on any patent that issues from this application.

The submission of this information disclosure statement by the Applicant(s) shall not be construed as a representation that a search has been performed or that no other material information under 37 C.F.R. § 1.56 exists. See 37 C.F.R. § 1.97(g).

The submission of this information disclosure statement by the Applicant(s) shall not be construed as an admission that any information cited or referred to herein is, or is considered to be, material to the patentability of one or more of the pending claims in this application pursuant to 37 C.F.R. § 1.56(b), unless specifically designated by the Applicant(s) as such. See 37 C.F.R. § 1.97(h).

The submission of this information disclosure statement by the Applicant(s) shall not be construed as an admission that any information cited or referred to herein is, or is considered to be, or even qualifies as "prior art" under 35 U.S.C. § 102 with respect to this invention, unless specifically designated by the Applicant(s) as such.


Notwithstanding any statements by the Applicant(s), the Examiner is urged to form his or her own conclusion regarding the relevance of the cited information.

## VI CONCLUSION

The Examiner is encouraged to contact the undersigned attorney to discuss any questions concerning this information disclosure statement or any of the information cited or referred to herein.

Respectfully submitted,

Date: 8 March 2004



Reed R. Heimbecher  
Reg. No. 36,353  
Attorney for Applicants  
**HEIMBECHER & ASSOC., LLC**  
**Customer No. 33486**  
200 Union Blvd., Suite 316  
Lakewood, CO 80228-1831  
Tel: 303-279-8888  
Fax: 303-985-0651

cc: Client  
Docketing

<b>FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE</b> (Modified) <b>PATENT AND TRADEMARK OFFICE</b>  <b>INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>ATTY. DOCKET NO.</b> 001-041501US	<b>SERIAL NO.</b> 10/608,257
	<b>APPLICANT:</b> Guy P. Vanney et al.	
	<b>FILING DATE</b> 27 June 2003	<b>GROUP</b>

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	PATENT NUMBER	ISSUE DATE	PATENTEE	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	5,348,554	20 Sep. 1994	M.A. Imran et al.			
	5,487,757	30 Jan. 1996	C. Truckai et al.			
	5,545,161	13 Aug. 1996	M.A. Imran			
	5,545,200	13 Aug. 1996	S.H. West et al.			
	5,785,706	28 Jul. 1998	M.C. Bednarek			
	5,826,576	27 Oct. 1998	S.H. West			
	5,906,605	25 May 1999	T. Coxum			
	5,938,694	17 Aug. 1999	R.S. Jaraczewski et al.			
	5,993,462	30 Nov. 1999	M.L. Pomeranz et al.			
	6,080,151	27 Jun. 2000	J.F. Swartz et al.			
	6,120,500	19 Sep. 2000	M.C. Bednarek et al.			
	6,169,916	2 Jan. 2001	S.H. West			
	6,251,109	26 Jun. 2001	J.A. Hassett et al.			
	6,264,654	24 Jul. 2001	J.F. Swartz et al.			
	6,325,797	4 Dec. 2001	M.T. Stewart et al.			
	6,447,507	10 Sep. 2002	M.C. Bednarek et al.			

## FOREIGN PATENT OR PUBLISHED FOREIGN PATENT APPLICATION

		DOCUMENT NUMBER	PUBLISHED DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

<b>EXAMINER</b>	<b>DATE CONSIDERED</b>	
<b>EXAMINER:</b> Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		